GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2010

Index Pledges €10M to New Company’s Development of Peptide Candidates for CNS Diseases

  • Index Ventures has pledged to provide up to a €10 million (about $14 million) investment in Mind-NRG, a newly incorporated Swiss CNS disease therapeutics firm. The new company is focused on the development of a peptidic neurotrophic factor candidate NRG-101, which it claims has disease-modifying potential and can cross the blood-brain barrier by receptor-mediated transport to reach its target. NRG-101 has been acquired from German systems biology firm ProteoSys in return for Mind-NRG equity.

    Funding from Index includes an initial €1.5 million in Series A financing, which will support research at Mind-NRG to generate additional key data on the drug. In the near-term the firm will focus on conducting in vitro and in vivo studies to further explore the peptide’s mechanism of action and its activity in a range of relevant disease models.

    Mind-NRG says it ultimately aims to develop NRG-101 for the treatment of neurological and psychiatric disorders including schizophrenia, Parkinson disease, and Alzheimer disease. Index Ventures partner Michèle Ollier has been appointed as Mind-NRG chairman.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?